Figure 6.

RP4010 potentiated the anti-cancer activity of gemcitabine/nab-paclitaxel in patient-derived xenograft (PDx). (A) H&E and immunostaining of tissue sections of the PDx tumors harvested from mice who received different treatments as well as from untreated controls. Images were taken at 200× magnification. (B and C) The mice with PDx were treated with either RP4010 or gemcitabine/nab-paclitaxel, or a combination of RP4010 with gemcitabine/nab-paclitaxel, and the effect of these treatments on tumor size and weight was assessed up to 50 days post-transplantation of PDx. Treatment started at 15 days post-transplantation when the tumors were palpable. All the tumors were collected 50 days post-transplantation at the culmination of the experiment.